Investors

Press Releases

Endonovo Therapeutics Highlights Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients
Endonovo Therapeutics Inc. to Move Forward with a Clinical Research Study Conducted by the Regents of the University of New Mexico
Endonovo Reports Positive Results in Critical Limb Ischemia Study Using Non-Invasive Medical Device
Endonovo Reports Pre-Clinical Data Demonstrating Immunotronics™ Reduced Infarct Size and Inhibited Fibrosis following Myocardial Infarction
Endonovo Announces First Commercial Sales for SofPulse Wearable Electroceutical for Post-Operative Pain and Edema
Endonovo Therapeutics Provides Corporate Update and 2018 Outlook
Endonovo Therapeutics Engages ShareIntel, A Leader In Shareholder Intelligence Services To Investigate Market Maker and Clearing Firm Irregularities
Endonovo Therapeutics Provides Update on Acquisition of PEMF Assets, Clinical Pipeline and Pre-Clinical Study
Endonovo Therapeutics Acquires Assets of Electroceuticals Developer, Rio Grande Neurosciences, and Settles Lawsuit
Endonovo Receives Positive Results from Pre-Clinical Study of Non-Invasive Electroceutical
RSS
Show All